[1] TORTAJADA-GIRBÉS M, BOUSQUET R, BOSQUE M, et al. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. Expert Rev Respir Med, 2018, 12(9): 745-754. [2] MACDONALD K M, KAVATI A, ORTIZ B, et al. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol, 2019, 15(5): 553-569. [3] FOLQUÉM M, LOZANO J, RIGGIONI C, et al. 'Real-life' experience in asthmatic children treated with omalizumab up to six-years follow-up. Allergol Immunopathol (Madr), 2019, 47(4): 336-341. [4] 中华医学会儿科学分会呼吸学组, 中华儿科杂志编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版). 中华儿科杂志, 2016, 54(3): 167-181. [5] Global Initiative for Asthma. Global strategy for asthma management and prevention main report 2019. (2019-11-12). [6] 奥马珠单抗治疗过敏性哮喘专家组, 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识. 中华结核和呼吸杂志, 2018, 41(3): 179-185. [7] 张映芬, 冯丽芬, 陈若青, 等. 儿童生存质量量表PedsQLTM 3. 0哮喘模块中文版父母报告的信度效度分析. 中山大学学报(医学科学版), 2010, 31(5): 710-714, 722. [8] ZONG X N, LI H. Construction of a new growth references for China based on urban Chinese children: Comparison with the WHO growth standards. PLoS ONE, 2013, 8(3): e59569. [9] MORALES-MUNERA O, PEDRAZA O-SERNA L. Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia. Rev Alerg Mex, 2018, 65(3): 222-232. [10] KE X, KAVATI A, WERTZ D, et al. Real-world clinical characteristics, treatment patterns, and exacerbations in US patients with asthma newly treated with omalizumab. Clin Ther, 2018, 40(7): 1140-1158. [11] BAYAR MULUK N, BAFAQEEH S A, CINGI C. Anti-IgE treatment in allergic rhinitis. Int J Pediatr Otorhinolaryngol, 2019, 127: 109674. [12] MOSTAFA B E, FADEL M, MOHAMMED M A, et al. Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis. European Archives of Oto-Rhino-Laryngology, 2020, 277(1): 121-128. [13] GARCÍA M, DURÁN-CRANE A, CHAPMAN E, et al. Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A serie of cases. Rev Alerg Mex, 2019, 66(3): 282-291. [14] VOLLONO L, PICCOLO A, LANNA C, et al. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice. Drug Des Devel Ther, 2019, 13: 3181-3186. [15] TÜRK M, BAH ECIOGLU S N, TUTAR N, et al. Omalizumab treatment for atopic severe persistant asthma: A single-center, long-term, real-life experience with 38 patients. Turk Thorac J, 2018, 19(4): 187-192. [16] HUMBERT M, ALBERS F C, BRATTON D J, et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med, 2019, 154: 69-75. [17] OLIVEIRA M J, VIEIRA M, COUTINHO D, et al. Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab. Pulmonology, 2019, 25(1): 15-20. [18] BADAR A, SALEM A M, BAMOSA A O, et al. Association Between FeNO, Total Blood IgE, Peripheral blood eosinophil and inflammatory cytokines in partly controlled asthma. J Asthma Allergy, 2020, 13: 533-543. [19] KELLY H W, STERNBERG A L, LESCHER R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med, 2012, 367(10): 904-912. [20] ZHANG L, LASMAR L B, CASTRO-RODRIGUEZ J A. The impact of asthma and its treatment on growth: an evidence-based review. J Pediatr (Rio J), 2019, 95(Suppl 1): 10-22. [21] OBLITAS C M, GALEANO-VALLE F, VELA-DE LA CRUZ L, et al. Omalizumab as a provoking factor for venous thromboembolism. Drug Target Insights, 2019, 13: 1177392819861987. [22] ALI A K, HARTZEMA A G. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy, 2012, 5: 1-9. |